Suche Bilder Maps Play YouTube News Gmail Drive Mehr »
Anmelden
Nutzer von Screenreadern: Klicke auf diesen Link, um die Bedienungshilfen zu aktivieren. Dieser Modus bietet die gleichen Grundfunktionen, funktioniert aber besser mit deinem Reader.

Patentsuche

  1. Erweiterte Patentsuche
VeröffentlichungsnummerUS20070026085 A1
PublikationstypAnmeldung
AnmeldenummerUS 11/189,242
Veröffentlichungsdatum1. Febr. 2007
Eingetragen26. Juli 2005
Prioritätsdatum26. Juli 2005
Auch veröffentlicht unterUS7638147, US20090004305, WO2007018615A1, WO2007018615A9
Veröffentlichungsnummer11189242, 189242, US 2007/0026085 A1, US 2007/026085 A1, US 20070026085 A1, US 20070026085A1, US 2007026085 A1, US 2007026085A1, US-A1-20070026085, US-A1-2007026085, US2007/0026085A1, US2007/026085A1, US20070026085 A1, US20070026085A1, US2007026085 A1, US2007026085A1
ErfinderWilliam Chandler
Ursprünglich BevollmächtigterGlobal Life Technologies Corp.
Zitat exportierenBiBTeX, EndNote, RefMan
Externe Links: USPTO, USPTO-Zuordnung, Espacenet
Antimicrobial and antiviral composition
US 20070026085 A1
Zusammenfassung
An antimicrobial and antiviral barrier composition for topical application to the proximal anterior nares includes an antiseptic solution in combination with cocos nucifera (coconut oil) and one or more citrus oils such as, for example, citrus sinensis (orange oil). Various embodiments may also include one or more of the following additional ingredients: lauric acid; d-limonene; soy oil; emu oil; grapefruit seed extract; glycine soja; aloe vera and a preservative, such as sodium benzoate.
Bilder(7)
Previous page
Next page
Ansprüche(20)
1. An antimicrobial, antiviral and antifungal composition comprising:
an antiseptic solution in an amount of between 5% and 75% by weight of the composition;
citrus sinensis in the amount of between 0.05% and 60% by weight of the composition; and
cocos nucifera in an amount of between 0.025% and 70% by weight of the composition.
2. The composition as recited in claim 1 wherein said antiseptic solution comprises USP ethyl alcohol.
3. The composition as recited in claim 1 wherein said antiseptic solution comprises hydrogen peroxide.
4. The composition as recited in claim 1 further comprising:
glycine soja.
5. The composition as recited in claim 1 further comprising:
de-limonene.
6. The composition as recited in claim 1 further comprising:
lauric acid.
7. The composition as recited in claim 1 further comprising:
emu oil.
8. The composition as recited in claim 1 further comprising:
sodium benzoate as a preservative.
9. The composition as recited in claim 1 further comprising:
soy oil.
10. The composition as recited in claim 1 further comprising:
grapefruit seed extract.
11. An antimicrobial, antiviral and antifungal composition comprising:
an antiseptic solution in an amount of between 5% and 75% by weight of the composition;
citrus sinensis in an amount of 0.05% and 60% by weight of the composition;
cocos nucifera in the amount of between 0.025% and 70% by weight of the composition; and
glycine soja in the amount of between 30% and 70% by weight of composition.
12. The composition as recited in claim 11 further comprising a preservative.
13. The composition as recited in claim 12 wherein said preservative is sodium benzoate.
14. The composition as recited in claim 11 further comprising:
d-limonene.
15. The composition as recited in claim 11 further comprising:
lauric acid.
16. The composition as recited in claim 11 further comprising:
emu oil.
17. The composition as recited in claim 11 further comprising:
soy oil.
18. The composition as recited in claim 11 further comprising:
grapefruit seed extract.
19. The composition as recited in claim 11 wherein said antiseptic solution comprises USP ethyl alcohol.
20. The composition as recited in claim 11 wherein said antiseptic solution comprises hydrogen peroxide.
Beschreibung
    BACKGROUND OF THE INVENTION
  • [0001]
    1. Field of the Invention
  • [0002]
    This invention relates to antiseptic compositions and, more particularly, to a nasal antiseptic barrier composition having antimicrobial, antiviral, and antifungal properties.
  • [0003]
    2. Discussion of the Related Art
  • [0004]
    In recent years, outbreaks of new and potentially deadly diseases such as Severe Acute Respiratory Syndrome (SARS) and the Avian Influenza have captured worldwide attention and concern. New and unusual strains of the flu virus have also emerged in the last few years and have spread throughout the world population at epidemic levels. It is believed that increases in world population, rapid travel between distance regions and high concentration of individuals in confined areas where there is poor air filtration (e.g. aircraft, trains, buses and tourist sites) have resulted in the increase in the number of, as well as mutation of, pathogenic organisms.
  • [0005]
    The onset of respiratory disease is primarily a result of inhalation of airborne pathogens through the nose and mouth. However, the oral cavity is better equipped to kill airborne pathogens before they can enter and infect the body. Specifically, saliva in the mouth captures many airborne pathogens before they are inhaled into the lungs. Once the saliva containing the pathogens is swallowed, stomach acids are highly effective in killing these pathogens before they can infect the body. The nasal passages, on the other hand, are less effective in trapping and killing microorganisms. Airborne pathogens inhaled through the nose usually enter the lungs where there can cause respiratory infection or other types of infection once these pathogens enter the blood stream.
  • [0006]
    World wide concern of epidemic outbreaks has lead to more drastic preventative measures including emergency mass production of new vaccines. Individuals have adopted preventive practices such as frequent hand washing and use of antiseptic hand lotions and wipes. While these are good practices to help reduce the possibility of infection, they are not long lasting and are usually only effective to kill germs that were on the hands or other areas of the body prior to cleansing. With little to no residual effect, the hands can become contaminated with pathogens shortly after washing.
  • [0007]
    Some societies have begun to use face masks as a means of protection against respiratory infections. Face masks are effective to prevent entry of pathogens into the respiratory system. However, the use of face masks is generally impractical, inefficient and socially unappealing.
  • [0008]
    Besides the concern for the health and well beings of individuals there are economic interests in preventing the spread on communicable diseases. For instance, over the course of just one year Americans suffer approximately 1 billion colds. The economic impact of the common cold is enormous. The National Center for Health Statistics (NCHS) estimates that over 70 million cases of the common cold in the United States required medical attention or resulted in restricted activities. Colds cause more than 50 million days of restricted activity and 25 million days lost from school and the work place. Overall, the estimated cost to the U.S. economy of the common cold and other related illnesses is approximately $150 billion per year.
  • [0009]
    Accordingly, there is an immediate need for more effective protection measures to decrease the spread of disease, and particularly respiratory infections that result from exposure to airborne pathogens.
  • SUMMARY OF THE INVENTION
  • [0010]
    The present invention is directed to an antimicrobial and antifungal barrier composition for topical application to the proximal anterior nares (rim surrounding the nostrils). The composition includes an antiseptic solution in combination with cocos nucifera (coconut oil) and one or more citrus oils such as, for example, citrus sinensis (orange oil). Examples of an antiseptic solution include one or more alcohols, such as ethyl alcohol, or hydrogen peroxide. The composition may include one or more additional ingredients, including: lauric acid; d-limonene; soy oil; emu oil; grapefruit seed extract; glycine soja; aloe vera and a preservative, such as sodium benzoate.
  • [0011]
    When properly applied to the skin surrounding the nostril openings, the composition has been proven effective in killing 99.99999% (7 log) or greater germs. This extremely efficient antimicrobial efficiency persists for at least 8 hours. Results from laboratory studies have shown efficacy in killing streptococcus (pneumoniae and pyogenes), staphylococcus aureus, mycobacterium smegmatis, and haemophilus influenza bacterias. The antimicrobial and antiviral composition of the present invention was further shown to be effective in eradicating the rhinovirus and influenza A virus (avian flu), as well as the corona virus. The corona virus is known to be the cause of SARS.
  • [0012]
    In addition to the anti-pathogen properties, the composition of the present invention has also been proven to help alleviate the body's immuno-response to many allergens including, but not limited to, dust mites, pollen, hay fever, animal dander, dust, particulate pollution, ozone, sulfur dioxide, and nitrogen oxide. The composition is effective in trapping these allergens and alleviating the body's response to their presence. In the case of ozone, SO2 and NO, the composition acts as a barrier in the nose and lessens the IGA response in the body. It is also believed that the composition works to lessen the Interleukin expression in the nose, especially ILB, commonly perspective for the inflammation response in the nasal cavity. A particularly effective formulation includes one or more of the following ingredients in combination with citrus oils, cocos nucifera and glycine soja: beeswax; bees milk; and fruit wax.
  • OBJECTS AND ADVANTAGES OF THE INVENTION
  • [0013]
    Considering the forgoing, it is a primary object of the present invention to provide an antimicrobial and antiviral composition for topical application to the anterior nostril openings for protecting against harmful exposure to airborne pathogens.
  • [0014]
    It is a further object of the present invention to provide a safe and highly effective antimicrobial and antiviral composition for topical application to the rim of each nostril to provide protection against a broad spectrum of harmful pathogens for at least 8 hours.
  • [0015]
    It is still a further object of the present invention to provide an antimicrobial and antiviral composition for topical application to the rim of each nostril to enhance the natural filtration properties of the nose.
  • [0016]
    It is yet a further object of the present invention to provide an antimicrobial and antiviral composition for topical application to the rim of the nostrils for trapping and killing airborne pathogens before these pathogens can replicate within the nasal cavity.
  • [0017]
    It is still a further object of the present invention to provide an antimicrobial and antiviral composition that significantly reduces the number of harmful pathogens that proliferate freely within the nasal cavity, thereby minimizing the degree and severity of potential respiratory infection.
  • [0018]
    It is still a further object of the present invention to provide an antimicrobial and antiviral composition of topical application to the rim of the nostrils, and wherein the composition has a pleasant scent and contributes to the lubrication and filtration of the nasal passages.
  • [0019]
    It is yet a further object of the present invention to provide an antimicrobial and antiviral composition for topical application to the rim of the nostrils, wherein the composition is effective in trapping allergens and alleviating the body's response to their presence.
  • [0020]
    These and other objects of the present invention are more readily apparent with reference to the detailed description which follows.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • [0021]
    The present invention is directed to a long lasting antimicrobial and antiviral barrier composition for topical application to the proximal anterior nares (skin surface surrounding the opening of the nostrils). The antimicrobial and antiviral composition of the present invention incorporates the use of one or more antiseptic solutions in combination with cocos nucifera (coconut oil) and citrus sinensis (orange oil). In one preferred embodiment, the antiseptic solution is USP ethyl alcohol. In another preferred embodiment, the antiseptic solution is hydrogen peroxide. Other alcohols and antiseptic agents are contemplated for use in the composition as the antiseptic solution, either alone or as a combination.
  • [0022]
    The essential ingredients of the composition are present according to the following percentages by weight of the composition:
    Amount
    Additional Ingredients (% by Weight of the Composition)
    Antiseptic solution between 5% and 75%
    Citrus Sinensis between 0.05% and 60%
    Cocos Nucifera between 0.025% and 70%
  • [0023]
    The antimicrobial and antiviral composition of the present invention may further include the following additional ingredients, alone or in combination: lauric acid; d-limonene; soy oil; emu oil; grapefruit seed extract; glycine soja; and a preservative such as sodium benzoate. These additional ingredients of the composition are present according to the following percentages by weight of the composition:
    Amount
    Additional Ingredients (% by Weight of the Composition)
    Lauric acid between 0.01% and 5%
    D-limonene between 0.01% and 5%
    Glycine Soja (soy oil) between 0.1% and 80%
    Emu oil between 0.1% and 10%
    Grapefruit Seed extract between 0.1% and 8%
    Aloe Vera between 0.1% and 30%
  • [0024]
    A further embodiment of the composition has been proven to help alleviate the body's immune-response to many allergens and pollutants. The following ingredients have been found to be effective in the composition when present according to the following percentages by weight of the composition:
    Amount
    Ingredients (% by Weight of the Composition)
    Beeswax between 0.01% and 30%
    Bees Milk between 0.01% and 30%
    Fruit Wax between 0.1% and 5%
  • [0025]
    Antiseptic solutions such as ethyl alcohol and hydrogen peroxide typically evaporate at a rapid rate. For this reason, when antiseptic solutions are used alone, they usually have little to no residual effect. The base oils of the composition, namely citrus sinensis and cocos nucifera, are effective to trap the antiseptic solution in a pseudo-emulsion antiseptic that remains active for an extended period of time. This allows the composition to have a long lasting antimicrobial and antiviral protection. The base oils also provide antimicrobial, antiviral and antifungal properties.
  • [0026]
    When the base oils are combined with the antiseptic solution, a synergistic effect is observed. For instance, the efficacy of any one of the base oils or the antiseptic solution, alone, does not exceed 99.99% (4 log). However, when all ingredients are combined in suitable ratios an unexpected removal efficiency rating (efficacy) of 99.99999% (7 log) or greater is achieved. This synergism is a key to the novelty of the composition, providing antimicrobial and antiviral kill levels that are significantly greater than those observed in connection with any of the ingredients individually or other known antimicrobials and antivirals.
  • [0027]
    The following examples demonstrate various combinations of ingredients, including the 3 essential ingredients, which have been observed to yield antimicrobial and antiviral kill rates of 7 log or greater.
  • EXAMPLE 1
  • [0028]
    Amount
    Ingredient (% by Weight of the Composition)
    USP Ethyl Alcohol (190 proof) 24.9%
    Cocos Nucifera   3%
    Citrus Sinensis   2%
    Glycine Soja   70%
    Sodium Benzoate (preservative)  0.1%
  • EXAMPLE 2
  • [0029]
    Amount
    Ingredient (% by Weight of the Composition)
    USP Ethyl Alcohol (190 proof) 34.8%
    Cocos Nucifera   3%
    Citrus Sinensis   2%
    Aloe Vera   3%
    Lauric Acid  .1%
    Glycine Soja   57%
    Sodium Benzoate (preservative)  0.1%
  • EXAMPLE 3
  • [0030]
    Amount
    Ingredient (% by Weight of the Composition)
    USP Ethyl Alcohol (190 proof) 54.8%
    Cocos Nucifera   10%
    Citrus Sinensis   5%
    Aloe Vera   30%
    Lauric Acid  .1%
    Glycine Soja  0.1%
  • EXAMPLE 4
  • [0031]
    Amount
    Ingredient (% by Weight of the Composition)
    USP Ethyl Alcohol (190 proof) 24.9%
    Cocos Nucifera   8%
    Citrus Sinensis   8%
    Aloe Vera 29.45%
    Lauric Acid  .2%
    Glycine Soja 29.45%
  • EXAMPLE 5
  • [0032]
    Amount
    Ingredient (% by Weight of the Composition)
    USP Ethyl Alcohol (190 proof) 24.9%
    Emu Oil   3%
    Citrus Sinensis   2%
    Glycine Soja   70%
    Sodium Benzoate (preservative)  0.1%
  • EXAMPLE 6
  • [0033]
    Amount
    Ingredient (% by Weight of the Composition)
    Glycine Soja  35%
    Citrus Sinensis  30%
    Cocos Nucifera  30%
    Bees Milk 4.9%
    Preservative 0.1%

    * FOR ALLERGENS AND POLLUTANTS
  • EXAMPLE 7
  • [0034]
    Amount
    Ingredient (% by Weight of the Composition)
    Bees Milk   50%
    Lecithin   10%
    Citrus Sinensis   20%
    Glycine Soja 19.9%
    Preservative  0.1%

    * FOR ALLERGENS AND POLLUTANTS
  • [0035]
    In use, the antimicrobial and antiviral composition is applied to the skin surface surrounding the opening of the nostrils according to the following instructions:
  • [0036]
    1). Shake the bottle (containing the composition) well to insure complete mixture of the ingredients.
  • [0037]
    2) Apply approximately 4 drops of the composition to the cotton tip of a cotton swab so that the cotton tip is fully saturated with the composition.
  • [0038]
    3). Place the thumb and index finger on the swab stem directly below the wetted cotton tip of the swab. Prepare to apply the composition to the rim of each nostril just past the nasal opening. Caution: Do not extend the swab into the nasal canal any further than the short length of the cotton tip of the swab (about 1 cm or 3.8″). The swab stem should never enter the nose.
  • [0039]
    4). Carefully place only the cotton tip of the swab just inside of the nostril opening. Using a gentle motion, make 3 or 4 circles to fully apply the composition to the rim of the nostril. Repeat this step for the other nostril.
  • [0040]
    5). Discard the swab. Gently squeeze the nostrils together to ensure even distribution of the solution about the rim surrounding each nostril opening.
  • [0041]
    In order to evaluate the antimicrobial efficacy of one sample of the composition when applied to the proximal external nares of human volunteers, the test study was conducted at Bioscience Laboratory, Inc. in Bozeman, Mont. The results of the study are set forth below.
  • [0000]
    Purpose of Study:
  • [0042]
    This study was designed to evaluate the persistent antimicrobial efficacy of one (1) test product intended for prevention of airborne illness when applied within the proximal nares (the first 0.25″ of a naris) and one (1) control material.
  • [0000]
    Scope of Study:
  • [0043]
    Thirty (30) human subjects were evaluated in this study. Twenty-five (25) human subjects were used to evaluate the test product, and five (5) human subjects were used to evaluate the control material (sterile deionized water). Samples were taken from the proximal nares (the first 0.25″ of the nostrilar canal). Baseline samples were collected a minimum of twenty-four (24) hours apart to allow recolonization of the normal flora. On the test day, the product was applied to each naris. Each naris was apportioned on a sagittal plane into two (2) sample sites, medial and lateral. Ten (10) samples each were taken for the two (2) hour±fifteen (15) minutes and four (4) hour±fifteen (15) minutes post-product exposures to the test product, and for the immediate (within one [1] minute of application) and four (4) hour±fifteen (15) minutes post-product exposures to the control material. Twenty (20) samples each were taken for the immediate (within one [1] minute of application), six (6) hour±fifteen (15) minutes, eight (8) hour±fifteen (15) minutes, and twelve (12) hour±fifteen (15) minutes post-product exposures to the test product.
  • [0000]
    Validation of the Neutralizer System:
  • [0044]
    A neutralization study was performed to assure the effectiveness of the neutralizers used in the diluting medium. The neutralization followed guidelines set forth in ASTM E 1054-02, Standard Test Methods for Evaluation of Inactivators of Antimicrobial Agents, except that the microorganism was added to the neutralizers prior to the addition of the test or comparison antiseptic. Staphylococcus aureus (ATCC #6538) was used as the challenge species in the neutralizer validation study. The neutralization study demonstrated that the antimicrobial activities of the test and reference products were effectively eliminated.
  • [0000]
    Adverse Events:
  • [0045]
    No Adverse Events were observed during or following completion of this study.
  • [0000]
    Results:
  • [0046]
    Table I presents the statistical summary of the log 10 recovery values with relation to use of the Test Product.
    TABLE I
    Statistical Summary of the log 10 Recovery Values for the Test Product
    Standard 95% Confidence log10
    Sample Sample Size Mean Deviation Interval Reduction
    Baseline 25 4.51 0.39 4.35 to 4.67 N/A
    Pooled
    Immediate 21 3.38 1.28 2.79 to 3.96 1.13
    Post-Product Exposure
    2 Hours 11 3.61 1.14 2.85 to 4.38 0.90
    Post-Product Exposure
    4 Hours 9 3.58 0.56 3.15 to 4.02 0.93
    Post-Product Exposure
    6 Hours 18 3.59 0.52 3.34 to 3.85 0.92
    Post-Product Exposure
    8 Hours 21 3.88 0.65 3.58 to 4.17 0.63
    Post-Product Exposure
    12 Hours 19 4.28 0.67 3.96 to 4.60 0.23
    Post-Product Exposure
  • [0047]
    Table II presents the Statistical Summary of the log 10 recovery values with relation to use of the Control Material (Sterile Deionized Water)
    TABLE II
    Statistical Summary of the log 10 Recovery Values for the Control Material
    Sterile Deionized Water
    Standard 95% Confidence
    Sample Sample Size Mean Deviation Interval log10 Reduction
    Baseline 5 4.31 0.49 3.70 to 4.92 N/A
    Pooled
    Immediate 10 4.66 0.59 4.24 to 5.08 0.00
    Post-Product Exposure
    4 Hours 10 4.23 0.63 3.78 to 4.68 0.08
    Post-Product Exposure

  • [0048]
    While the composition of the present invention has been described and exemplified according to several preferred embodiments thereof, it is recognized that departures from the instant disclosure are fully contemplated within the spirit and scope of the invention which is not to be limited except as defined in the following claims as interpreted under the Doctrine of Equivalents.
Patentzitate
Zitiertes PatentEingetragen Veröffentlichungsdatum Antragsteller Titel
US3824304 *5. Juni 197216. Juli 1974Villanueva AHair conditioner
US4140759 *13. Juli 197720. Febr. 1979Helena Rubinstein, Inc.Protein shampoo
US6696067 *12. Apr. 200124. Febr. 2004Ondeo Nalco CompanyCosmetic compositions containing dispersion polymers
US20040234491 *8. Juni 200425. Nov. 2004Kpss-Kao Professional Salon Services GmbhHair conditioning composition
US20050069509 *30. Sept. 200331. März 2005Francis BuschOxygen rich scalp treatment
Referenziert von
Zitiert von PatentEingetragen Veröffentlichungsdatum Antragsteller Titel
US889528220. März 200925. Nov. 2014Tanomed AbUse of a substance for manufacturing of a medicament for treatment of common cold
US20100021563 *24. Juli 200928. Jan. 2010Paul LevesqueCompositions comprising coconut oil and methods of use thereof
US20110044966 *20. März 200924. Febr. 2011Krister TanoUse of a substance for manufacturing of a medicament for treatment of common cold
US20130287714 *12. Nov. 201031. Okt. 2013Sven GohlaCosmetic and/or dermatological preparations containing snow algae extract
WO2009116944A1 *20. März 200924. Sept. 2009Krister TanoUse of a substance for manufacturing of a medicament for treatment of common cold
Klassifizierungen
US-Klassifikation424/522, 514/568, 514/642, 424/736, 424/616, 424/757, 514/558, 514/763, 424/776
Internationale KlassifikationA61K33/40, A61K31/20, A61K36/752, A61K35/12, A61K36/48, A61K31/14
UnternehmensklassifikationA61K36/889, A61K31/015, A61K31/045, A61K33/40, A61K36/886, A61K31/14, A61K36/48, A61K36/752, A61K31/20, A61K35/57
Europäische KlassifikationA61K31/015, A61K31/045, A61K36/48, A61K36/886, A61K36/889, A61K31/20, A61K33/40, A61K36/752, A61K31/14, A61K35/12
Juristische Ereignisse
DatumCodeEreignisBeschreibung
26. Juli 2005ASAssignment
Owner name: GLOBAL LIFE TECHNOLOGIES CORP., FLORIDA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHANDLER, WILLIAM;REEL/FRAME:016818/0100
Effective date: 20050725